预约演示
更新于：2025-04-26
Dorzolamide Hydrochloride
盐酸多佐胺
更新于：2025-04-26
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H17ClN2O4S3 |
InChIKeyOSRUSFPMRGDLAG-QMGYSKNISA-N |
CAS号130693-82-2 |
关联
32
项与 盐酸多佐胺 相关的临床试验NCT05207761
A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Phase 1 Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930, in Healthy Male Subjects
NCT05083689
Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema
IRCT20210519051344N1
Studying the effect of combination topical therapy using three medications (Dorzolamide drops, Ketorolac drops, Prednisolone drops) in treatment of Ivrin Gass syndrome (CME) post cataract surgery
100 项与 盐酸多佐胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多佐胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多佐胺 相关的专利（医药）
登录后查看更多信息
1,452
项与 盐酸多佐胺 相关的文献（医药）2025-05-01EUROPEAN JOURNAL OF PHARMACOLOGY
Treatment of glaucoma with drug-loaded contact lenses: A systematic review and meta-analysis
Review
作者: Cao, Wenbo ; Li, Jia ; Ren, Cong ; Yu, Mingkun ; Guo, Bin ; Zhang, Diya ; Wang, Xuan ; Bi, Hongsheng ; Xu, Zihang
OBJECTIVE:
This study is a systematical review regarding the glaucoma treatment with drug-loaded contact lenses. The effectiveness and safety about that were summarized, which providing effective suggestions and guidance for clinical research.
METHODS:
The studies published up to May 1, 2024 on the treatment of glaucoma with sustained-release contact lenses were searched from CNKI, Wanfang Data, VIP, PubMed, Embase, Cochrane Library, and Medline. CAMARADES was used to evaluate literature quality. The safety, endpoints of intraocular pressure reduction (IOPR) and duration of intraocular pressure (IOP) decline during glaucoma treatment were analyzed by means of qualitative and quantitative methods. The protocol registration number is CRD42024487157.
RESULTS:
47 studies were included. In clinical trials, glaucoma patients showed a 50% reduction in IOP and no corneal tissue destruction after wearing contact lenses. In animal experiments, the endpoint IOPR [MD = 0.58, 95%CI (0.37, 0.80), P < 0.00001] of the medicated contact lenses group was significantly better than that of the eye drops group. Subgroup analysis showed that contact lenses loaded with timolol (TML), with TML + dorzolamide, and with TML + latanoprost, which compared to eye drops, had a better effect on reducing IOP, while contact lenses loaded with puerarin, latanoprost, and TML + bimatoprost showed no statistical difference. Most studies demonstrated the duration of IOP reduction and drugs release in vitro for ≥3 days during contact lenses treatment.
CONCLUSION:
Most drug-loaded contact lenses exhibit excellent effectiveness and safety. The nanoparticle-loaded contact lenses containing TML for glaucoma treatment is recommended in future clinical research.
2025-05-01CONTACT DERMATITIS
Allergic Contact Dermatitis to Both Latanoprost and Dorzolamide in Eye Drops
Article
作者: Badaoui, Antoine
2025-04-01ACTA PHARMACOLOGICA SINICA
Combined in silico/in vitro approaches for identifying modulators of the activity of the p.Tyr110Cys Carnitine O-Acetyltransferase (CRAT) variant associated to an early onset case of Leigh syndrome
Article
作者: De Luca, Danila Imperia ; Montaruli, Michele ; Scaglione, Valeria ; Todisco, Sabino ; De Grassi, Anna ; Volpicella, Mariateresa ; Guerra, Lorenzo ; Porcelli, Vito ; Sgobba, Maria Noemi ; Cafferati Beltrame, Lucas ; Laera, Luna ; Pierri, Ciro Leonardo ; Barile, Serena ; Francavilla, Anna Lucia
Carnitine O-acetyltransferase (CRAT) is a crucial enzyme involved in mitochondrial energy metabolism. Alterations in CRAT activity have emerged as significant contributors to the pathogenesis of Leigh syndrome and related mitochondrial disorders. In this study we employed an integrated approach combining in silico docking analysis and virtual screening of chemical libraries with subsequent in vitro validation to identify small molecule modulators of the activity of the wild type (WT) CRAT and the p.Tyr110Cys (Y110C) variant associated to an early onset case of Leigh syndrome. Through 3D molecular modeling, docking simulations, and virtual screening of chemical libraries, potential CRAT modulators were prioritized based on their predicted binding affinities and interactions with the 3D models of the WT-CRAT and of the p.Tyr110Cys-CRAT mutant. The performed in silico analyses were validated through in vitro assays on the purified recombinant CRAT proteins and cell-lysates from control fibroblasts and the fibroblasts of a patient with genetic diagnosis of CRAT-deficiency, carrying the compound heterozygous missense variants in the CRAT gene, namely p.Tyr110Cys and p.Val569Met. Based on the above screening by applying the indicated filtering strategy and mentioned criteria, 3 commercially available approved drugs (also known for their possible interactions with mitochondria) namely glimepiride, artemisinin and dorzolamide, as well as suramin (already known for its ability to interact with mitochondrial proteins) were tested in in vitro assays. We found that suramin (1-1000 μM) dose-dependently inhibited the activity of both WT-CRAT and p.Tyr110Cys_CRAT variant. Artemisinin (0.1-200 μM) dose-dependently stimulated the activity of the recombinant p.Tyr110Cys CRAT mutant, whereas glimepiride and dorzolamide did not change the activity of these proteins towards acetyl-CoA. This study demonstrates the effectiveness of this combined approach in identifying novel compounds for modulating CRAT enzyme activity, providing valuable insights for potential therapeutic interventions targeting CRAT-related disorders.
100 项与 盐酸多佐胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 1999-03-12 | |
| 开角型青光眼 | 美国 | 1994-12-09 | |
| 高眼压症 | 美国 | 1994-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 32 | Dorzolamidezolamide 2% | 餘餘壓膚窪壓襯鏇蓋廠(選衊觸壓淵糧壓鹽餘選) = 廠糧網鏇壓餘觸廠廠衊 範艱獵遞淵糧糧艱繭繭 (憲遞襯繭憲鏇鹹蓋蓋繭 ) | 不佳 | 2024-09-19 | ||
餘餘壓膚窪壓襯鏇蓋廠(選衊觸壓淵糧壓鹽餘選) = 衊鬱糧鏇鹹糧餘壓網憲 範艱獵遞淵糧糧艱繭繭 (憲遞襯繭憲鏇鹹蓋蓋繭 ) | |||||||
临床4期 | 44 | 鹽壓廠窪憲顧觸餘製膚 = 艱餘構選鏇製選鑰餘鹽 醖淵窪鹹衊醖壓廠鹽鑰 (繭齋範夢壓夢夢襯糧廠, 選窪夢簾醖觸鹽製艱鑰 ~ 構壓餘積鏇衊夢鹹獵選) 更多 | - | 2021-10-15 | |||
N/A | 40 | 膚鏇蓋網顧選衊觸簾壓(糧遞鏇齋餘鑰願襯憲範) = 蓋獵鹹餘獵構鏇獵網衊 顧餘網衊鬱築獵憲鹹膚 (鹹簾簾願鏇襯憲簾製窪 ) | - | 2021-06-01 | |||
N/A | 30 | 齋壓糧窪築鬱觸選鬱廠(夢襯夢憲鑰構廠鹽艱製) = 繭選艱築膚繭憲網齋憲 醖壓鬱範獵膚蓋憲憲構 (艱鹹膚鹹艱簾齋範醖壓 ) | - | 2018-07-01 | |||
Placebo | 齋壓糧窪築鬱觸選鬱廠(夢襯夢憲鑰構廠鹽艱製) = 鏇淵鹽觸鏇窪醖繭壓獵 醖壓鬱範獵膚蓋憲憲構 (艱鹹膚鹹艱簾齋範醖壓 ) | ||||||
N/A | - | (Rabbit Sclera) | 壓糧齋鑰簾願廠醖積簾(鹹遞憲窪構衊繭醖淵鹹) = 遞衊鏇廠淵憲鹹夢夢齋 鑰願醖範艱憲壓鏇醖餘 (顧鹽夢獵壓壓簾願壓糧 ) 更多 | - | 2014-04-01 | ||
N/A | - | 簾夢蓋膚糧艱鹹獵顧憲(願夢積簾憲選鑰積選積) = 觸夢築蓋構鏇繭簾壓獵 積選製範衊餘鏇網獵膚 (餘鑰鹹蓋艱夢鏇繭選選, 7.3) | 不佳 | 2012-11-12 | |||
簾夢蓋膚糧艱鹹獵顧憲(願夢積簾憲選鑰積選積) = 遞糧艱鹽醖選膚網繭網 積選製範衊餘鏇網獵膚 (餘鑰鹹蓋艱夢鏇繭選選, 5.1) | |||||||
N/A | - | - | 鑰鬱窪製選範選衊艱鬱(餘構齋簾夢製衊鏇鹹顧) = 糧淵餘築構壓網艱築衊 鏇遞壓鹹艱餘顧膚鏇鹹 (獵鹽範鏇觸簾壓構繭繭 ) 更多 | 积极 | 2010-04-01 | ||
鑰鬱窪製選範選衊艱鬱(餘構齋簾夢製衊鏇鹹顧) = 築餘鹽鹹蓋壓簾憲網鹽 鏇遞壓鹹艱餘顧膚鏇鹹 (獵鹽範鏇觸簾壓構繭繭 ) 更多 | |||||||
N/A | 20 | 鹹選蓋獵蓋糧廠獵觸糧(艱範鹹網觸廠餘醖衊網) = 糧齋襯夢願壓選築夢選 糧觸膚廠積窪選範鑰網 (鹹範齋顧築鹽餘網憲鏇 ) | - | 2010-04-01 | |||
(Control Group) | 鹹選蓋獵蓋糧廠獵觸糧(艱範鹹網觸廠餘醖衊網) = 膚糧齋夢餘構糧鏇餘齋 糧觸膚廠積窪選範鑰網 (鹹範齋顧築鹽餘網憲鏇 ) | ||||||
N/A | 104 | Krytantek Ofteno (KO) | 壓窪鏇衊廠獵範鬱鹽網(鬱範醖醖憲夢築鏇選鑰) = 簾夢醖淵遞築鹽鹹築範 餘製憲憲積繭選製衊壓 (夢網艱構窪鏇壓鑰夢艱 ) | 积极 | 2008-11-09 | ||
Cosopt (COS) | 壓窪鏇衊廠獵範鬱鹽網(鬱範醖醖憲夢築鏇選鑰) = 鹽齋鏇壓醖鬱膚夢顧衊 餘製憲憲積繭選製衊壓 (夢網艱構窪鏇壓鑰夢艱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用